Intervention not reported
Creatinine phosphate 1g/day for 6 months · patients with heart failure
1 finding from 1 review
Intervention not reported
Creatinine phosphate 1g/day for 3 months · patients with heart failure
1 finding from 1 review
All causes of mortality at 30 days · Anticoagulants in ACS
Factor Xa inhibitors showed no clear difference in all causes of mortality at 30 days compared with anticoagulants (high certainty).
1 finding from 1 review
All causes of mortality at 30 days ‐ UFH · Anticoagulants in ACS
Factor Xa inhibitors showed no clear difference in all causes of mortality at 30 days ‐ UFH compared with anticoagulants (high certainty).
1 finding from 1 review
All causes of mortality at 30 days ‐ Enoxaparin · Anticoagulants in ACS
Factor Xa inhibitors leads to lower all causes of mortality at 30 days ‐ Enoxaparin compared with anticoagulants (high certainty).
1 finding from 1 review
Major bleeding · Anticoagulants in ACS
Factor Xa inhibitors showed no clear difference in major bleeding at 30 days compared with anticoagulants (high certainty).
2 findings from 1 review
Major bleeding at 30 days ‐ Enoxaparin · Anticoagulants in ACS
Factor Xa inhibitors leads to higher major bleeding at 30 days ‐ Enoxaparin compared with anticoagulants (high certainty).
1 finding from 1 review
Minor bleeding · Anticoagulants in ACS
Factor Xa inhibitors showed no clear difference in minor bleeding at 30 days compared with anticoagulants (high certainty).
3 findings from 1 review
RR 0.7 [0.14, 3.39]
2 studies · 20404 participants
High
RR 1.76 [0.52, 5.94]
1 study · 326 participants
Moderate
RR 0.34 [0.28, 0.43]
1 study · 20078 participants
High
Length of hospital stay · patients with colorectal surgery
1 finding from 1 review
60‐day mortality ‐ Aprotinin versus control · Patients with liver transplantation.
It is very uncertain whether intervention changes 60‐day mortality ‐ Aprotinin versus control compared with control (very low certainty).
1 finding from 1 review
60‐day mortality ‐ Tranexamic acid versus control · Patients with liver transplantation.
It is very uncertain whether intervention changes 60‐day mortality ‐ Tranexamic acid versus control compared with control (very low certainty).
1 finding from 1 review
60‐day mortality ‐ Recombinant factor VIIa (rFVIIa) versus control · Patients with liver transplantation.
It is very uncertain whether intervention changes 60‐day mortality ‐ Recombinant factor VIIa (rFVIIa) versus control compared with control (very low certainty).
1 finding from 1 review
60‐day mortality ‐ Tranexamic acid versus aprotinin · Patients with liver transplantation.
It is very uncertain whether intervention changes 60‐day mortality ‐ Tranexamic acid versus aprotinin compared with control (very low certainty).
1 finding from 1 review
Length of hospital stay · Patients with cancer receiving chemotherapy and/or radiotherapy with overt oral candidiasis
The review found no eligible studies for this question.
1 finding from 1 review
None of the studies reported: relief of pain, relief of dysphagia, incidence of systemic infection, amount of analgesia, days stay in hospital, cost of oral care, patient quality of life.
0 studies
No studies found
Time to heal mucositis (days) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Chlorhexidine mouthwash showed no clear difference in time to heal mucositis (days) compared with salt and soda mouthwash; GRADE not reported.
1 finding from 1 review
Time to heal mucositis (days) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
'Magic' mouthwash (lidocaine, diphenhydramine, aluminium hydroxide) showed no clear difference in time to heal mucositis (days) compared with salt and soda mouthwash; GRADE not reported.
1 finding from 1 review
Reduction in pain duration (percentage of day) · Adult patients aged >=18 years, clinically or radiographically diagnosed with TMD (McNeill 1997 criteria); moderate to severe pain of…
Oral propranolol (beta-blocker) showed no clear difference in reduction in pain duration (percentage of day) compared with placebo; GRADE not reported.
1 finding from 1 review
Time to heal mucositis (days) · People with cancer receiving chemotherapy or radiotherapy (or both) who have oral mucositis
Granulocyte macrophage-colony stimulating factor (GM-CSF) showed no clear difference in time to heal mucositis (days) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Intervention not reported
Treatment failure at 8 to 19 days · patients with acute otitis media
The intervention led to higher treatment failure at 8 to 19 days; GRADE not reported.
1 finding from 1 review
Intervention not reported
Treatment failure at 20 to 30 days · patients with acute otitis media
The intervention showed no clear difference in treatment failure at 20 to 30 days; GRADE not reported.
1 finding from 1 review